The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...
The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.
Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...
Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics ...
Tenaya Therapeutics (TNYA) announced interim data from the ongoing RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for the potential ...
Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy December 9, 2025 3:00 ...
The CVCT Forum is an annual, invite-only workshop that aims to cultivate a multi-stakeholder exchange to enhance clinical trials, streamline regulatory approval processes, and facilitate the ...
Patients requiring extracorporeal membrane oxygenation -- a type of heart-lung bypass therapy -- typically need extended bed rest, due to ...
Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” ...
In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback